However, many clinical trials have been halted due to severe side effects due to CXCL12 antagonism and the main CXCR4 antagonist used in the clinic is AMD3100 to boost stem cell mobilization in lymphoma and myeloma patients (71). Here, CXCL12 is linked to plasma cell myeloma.